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ABSTRACT
Introduction. Methotrexate (MTX) is an immunosuppressive and 
anti-inflammatory drug used to treat rheumatoid arthritis (RA) and 
other autoimmune conditions. MTX is transported into cells, where 
glutamate moieties are added and is retained as methotrexate poly-
glutamates (MTXPGs). In the RA literature, it has been reported that 
the degree of polyglutamation correlates with the anti-inflammatory 
effect of MTX in RA. There are no prior studies evaluating the rela-
tionship between MTXPGs and myasthenia gravis (MG) outcome 
measures. The objective of this study was to assess the correlation 
between methotrexate (MTX) polyglutamates (MTXPGs) with 
Myasthenia Gravis (MG) outcome measures.
Methods.xAn analysis was done of blood drawn from patients 
enrolled in the 12-month randomized, placebo-controlled study of 
MTX in MG study. Red blood cell MTXPGs were measured via ultra-
performance liquid chromatography and tandem mass spectrometry. 
MTXPG was correlated to MG outcome measures using Spearman 
Correlation Coefficient. A two-group t-test was used to determine 
the difference in MTXPG based on clinical outcome responder defi-
nitions.
Results. Twenty-one polyglutamate samples were analyzed of sub-
jects on MTX while eight samples were analyzed from subjects on 
placebo. Pentaglutamate had the strongest correlation with the 
MG-ADL (0.99), while tetraglutamate had the strongest correlation 
with the QMG (0.54). Triglutamate had the strongest correlation 
with MGC (0.76).
Conclusion. There were variable correlations between MTXPG1-5 
and MG outcomes (rho range: 0.08 to 0.99). There are strong corre-
lations between MTXPG and the MG-ADL, QMG, and MGC. Long 
chain methotrexate polyglutamates correlate better with MG out-
comes. Kans J Med 2020;13(Suppl 2):10-13.
INTRODUCTION
Methotrexate (MTX) is a disease-modifying antirheumatic drug 
(DMARD) used in the management of rheumatoid arthritis (RA). 
Methotrexate is a folate analogue, used in treatment of cancers and 
autoimmune diseases. Given orally or subcutaneously, MTX is trans-
ported into cells, where additional glutamate moieties are added 
and is retained as methotrexate polyglutamates (MTXPGs). Prior 
studies suggest the degree of polyglutamation correlates with the 
anti-inflammatory effect of MTX in RA. There are no prior studies 
evaluating the relationship between MTXPGs and myasthenia gravis 
(MG) outcome measures.
Although the full molecular anti-inflammatory mechanism of 
MTX is not clearly elucidated, it is known that MTX acts as a folate 
antagonist. Once intracellular, MTX is bioactivated to the polyglu-
tamated form of methotrexate (MTXglun) by folylpolyglutamyl 
synthase (FPGS), which promotes cellular retention and inhibi-
tion of several enzymes.1 No or low glutamation leads to the efflux 
of MTX by the ATP-binding cassette (ABC) family of transporters. 
FPGS and ABCG2 are of particular interest as folate deprivation has 
been associated with increased expression of FPGS and decreased 
expression of ABCG2,2 suggesting a cellular response to low folate 
with an increase in polyglutamation and decrease in folate export to 
promote retention of folate within the cell. Additionally, upregula-
tion of ABCG2 protein expression has been associated with MTX 
resistance in cancer cells.  Therefore, allelic variation in these genes 
resulting in increased or decreased activity may be associated with 
either increased or decreased MTXglun. This entire process is also 
likely dependent upon the folate status of the patient, reflected by the 
polyglutamation of folate itself, and the relative concentrations of the 
two groups of mutually antagonistic compounds.  
As serum MTX concentrations have been notoriously unreliably 
associated with MTX clinical outcomes,3-5 the search for more stable 
biomarkers of diseases response to MTX have been ongoing.  An 
association between RBC MTXglun and effectiveness of MTX in RA 
has been reported.6-7  Higher levels of  “long chain MTXglun” (defined 
as MTXglu3 or greater) were associated with improved effectiveness 
of MTX in RA.  There has also been reported variability of MTXglun 
concentrations and patterns associated with MTX dosing route 
and dose of administration in Juvenile Idiopathic Arthritis patients 
prescribed this medication.8 Since RBC folate concentrations are 
established during erythropoiesis and represent the average folate 
status over the preceding 120 days,9 by extension, MTX concentra-
tions in RBCs are a surrogate biomarker of average drug exposure 
over a similar period of time.  Furthermore, methotrexate polyglu-
tamates in RBCs are considered to be representative of intracellular 
MTX levels in target tissues, are more stable than serum levels of 
MTX, and may potentially predict response to the drug.6-7, 10-11
Methotrexate may also cause hepatotoxicity,12 probably as a 
result of accumulation in the liver as polyglutamates13 and can cause 
increases in serum alaninine aminotransferace (ALT) and aspartate 
aminotranseferase (AST).14 Renal impairment is a significant con-
tributing factor to the occurrence of toxicities in other organ system, 
particularly hematopoietic and gastrointestinal systems. Whether 
methotrexate produces some degree of renal insufficiency has not 
been clearly established. Headache, dizziness, vertigo, mood changes, 
seizures, ataxia and cognitive impairment have been infrequently 
described.15
10This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License. (CC-BY-NC-ND 4.0: https://creativecommons.org/licenses/by-nc-nd/4.0/)
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We performed a randomized-controlled trial of oral methotrexate 
in myasthenia gravis involving 50 subjects at 19 sites.16 Myasthenia 
gravis is an autoimmune disease with antibodies derived against the 
acetylcholine receptor in muscle at the neuromuscular junction.17 
Prednisone is the first line immunosuppressive therapy for MG.18 
We studied if methotrexate would be of benefit to MG patients on 
prednisone. In this study, we failed to show MTX subjects were on 
a lower prednisone dose at the end of twelve months, which was 
our primary endpoint. Secondary endpoints such as the Quantita-
tive Myasthenia Gravis (QMG) and Myasthenia Gravis - Activities 
of Daily Living (MG-ADL) showed trends toward greater improve-
ment in MTX subjects but did not meet statistical significance in the 
pre-determined intent-to-treat analysis. When alternative intent-
to-treat analyses were done post-hoc, QMG and MG-ADL did meet 
significance. We also performed polyglutamation blood studies on 
participants at the conclusion of the 12-month study.
METHODS
Trial Design. Analysis was done on blood drawn from patients 
enrolled in the 12-month randomized, placebo-controlled study of 
MTX in MG. Red blood cell MTXPGs were measured via ultra-per-
formance liquid chromatography and tandem mass spectrometry.19 
MTXPG was correlated to MG outcome measures using Spearman 
Correlation Coefficient. 
Standard Protocol Approvals, Registrations, and Patient Con-
sents. The trial was approved by the Institutional Review Board at 
the University of Kansas Medical Center. Written informed consent 
was obtained by all participants, in accordance with the Declaration 
of Helsinki and the principles of Good Clinical Practice. 
Outcomes and Measures. Monoglutamate (1), diglutamate (2), 
triglutamate (3), tetraglutamate (4), and pentaglutamate (5) were 
analyzed for correlation to the MG-ADL scale, the QMG scale, and 
the Myasthenia Gravis Composite (QMC) scale, all standard MG 
research outcome measures. 
Statistics. A total of 33 polyglutamate samples were collected in 
the study and 21 samples were used from subjects who were on active 
MTX for analysis. The differences of the outcome measures between 
the baseline and end of study visit was calculated. A two-group t-test 
was used to determine the difference in MTXPG based on clinical 
outcome responder definitions. We correlated MTXPG1-5 to MG 
outcome measures using Spearman Correlation Coefficient.
RESULTS
A total of 33 polyglutamate samples were collected in the study. 
Twenty-five samples were from subjects on MTX and eight samples 
were from subjects on placebo. Twenty-one samples were used for 
analysis (Figure 1). The median age of subjects was 64 ± 11.3 and the 
male/female ratio was 16:5.
Figure 1. Study design. 
The results of the degree of polyglutamation for each sample 
are shown in Figure 2. There were variable correlations between 
MTXPG1-5 and MG outcomes with a rho range: 0.08 to 0.99 (Table 
1). Strong correlations were seen between MTXPG2,4,5  and MGADL, 
MTXPG4,5 with QMG and MTXPG3 with MGC. Both coefficients lie 
between -1 and +1. The more the correlation coefficient comes closer 
to -1 or 1, the more there is a correlation between two variables. Our 
interpretation of strength of correlation in this study is as follows: < 
0.15 = very weak, 0.15 – 0.25 = weak, 0.25 – 0.40 = moderate, 0.40 – 
0.75 = strong, >0.75 = very strong (Table 1).
Figure 2. Degree of methotrexate polyglutamation in MG subjects.
Table 1. Correlation of methotrexate polyglutamation and MG. 
Polyglutamates* Correlation with MG outcomes (rho)
MG-ADL QMG MGC Prednisone dose
Monoglutamates 0.20 0.08 0.08 0.17
Diglutamates 0.60 0.02 0.39 0.14
Triglutamates 0.38 0.19 0.76 0.36
Tetraglutamates 0.71 0.54 0.30 0.30
Pentaglutamates 0.99 0.53 0.15 -0.18
MG-ADL = Myasthenia Gravis Activities of Daily Living; QMG = Quantitative 
Myasthenia Gravis; MGC = Myasthenia Gravis Composite
*Bolded are strong and very strong correlations.
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We found that the therapeutic effect of MTXPGs correlates with 
MG clinical outcome measures used in our prospective randomized 
trial. The therapeutic effects of MTX in RA depend on its conversion 
to MTXPGs, so measuring intracellular MTXPGs has been proposed 
as an objective method to guide MTX therapy in various disease 
conditions. Most of the information on MTXPG is from rheumatoid 
arthritis literature. Methotrexate helps stabilize rheumatoid arthritis 
conditions. Long chain MTXPGs stay in the cell longer than short 
chain MTXPG; therefore, long chain MTXPG keeps MTX in active 
form longer inside the cell, hence possibly allowing MTX to work 
longer.  Rheumatoid arthritis literature showed higher concentra-
tions of RBC long chain MTXPGs were associated with increased 
therapeutic response to MTX. However, literature is limited in other 
conditions. 
This is the first study studying MTXPGs in Myasthenia Gravis 
and correlating it with outcomes in a randomized-controlled trial. 
We showed a wide inter-patient variability of RBC MTXPG concen-
trations in patients receiving similar dose of MTX therapy, which 
is similar to the rheumatoid arthritis literature. Also similar to the 
rheumatoid literature, the long chain polyglutamates (tetra and 
penta) correlated well with outcomes. In this case outcomes used 
were QMG, MG-ADL, and MGC. Prior studies showed no statistical 
significance of the MTXPGs levels with side effects; however, this 
analysis was not performed in our study. Of note, none of the subjects 
who were part of this sub-study developed liver toxicity. 
Although the phase II Methotrexate in MG trial was negative 
(did not show significant reduction in the prednisone dose under the 
curve), the polyglutamate analysis showed strong correlations with 
MG outcome measures. This supported our other findings that sec-
ondary outcomes showed trends in improvement when patients were 
on methotrexate versus placebo.
As a result of this analysis, we believe that polyglutamation may be 
a useful personalized medicine biomarker to predict clinical improve-
ment in MG when patients are on methotrexate. However, further 
studies should be done using this tool in myasthenia gravis.
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